Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Evaluation of the Efficacy of QUITOXIL® in Smoking Cessation

NCT: NCT07722832 · NOT_YET_RECRUITING

NCT IDNCT07722832
StatusNOT_YET_RECRUITING
Start Date2026-10-01
Completion2028-04-01
SponsorKLAVA Innovation (INDUSTRY)
First posted
Last updated

Brief Summary

As part of post-marketing clinical monitoring and with a view to applying for the digital medical device Quitoxil® to be included on the LPPR list, this prospective, multicentre, controlled, randomised clinical trial aims to evaluate the clinical impact of support provided by Quitoxil® as an adjunct to conventional management for patients undergoing smoking cessation who have a tobacco use disorder.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑